The evolving role of genomics in the treatment of WM: MYD88, CXCR4, and TP53
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the evolving role of genomics in the treatment of Waldenström's macroglobulinemia (WM), highlighting the significance of the MYD88, CXCR4, and TP53 mutations. He mentions the potential of targeted therapies dependent on the mutational status of individual patients. This interview took place at the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Watch video The evolving role of genomics in the treatment of WM: MYD88, CXCR4, and TP53 online without registration, duration hours minute second in high quality. This video was added by user VJHemOnc – Video Journal of Hematology & HemOnc 24 October 2024, don't forget to share it with your friends and acquaintances, it has been viewed on our site 114 once and liked it 1 people.